Nomogram based on Prognostic Nutritional Index (PNI) for predicting acute radiation proctitis in locally advanced rectal cancer patients with neoadjuvant chemoradiotherapy
PeerJ · 02.06.2026 · 14 · e21364
DOI: 10.7717/peerj.21364 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, online erschienen am 02.06.2026. Verfasst von Yao Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Nomograms, Proctitis, Rectal Neoplasms, Neoadjuvant Therapy. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Radiation-induced proctitis is a frequent adverse effect that negatively impacts the quality of life in rectal cancer patients receiving neoadjuvant chemoradiotherapy (nCRT). Identifying high-risk factors and predicting their occurrence are crucial for preventing acute radiation proctitis (ARP). The aim of this study was to identify potential risk factors and develop a nomogram to predict the risk of ARP.
Methods
A total of 561 locally advanced rectal cancer (LARC) patients from January 1, 2019 to December 31, 2021 were collected. Patients were randomly allocated to the training and validation cohorts in a 7:3 ratio. Univariate and multivariate logistic regression analyses were conducted to determine potential predictive factors. A nomogram was created using predictive factors for ARP. The model’s performance was assessed using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA).
Results
Among 561 patients, 131 were diagnosed with ARP within 90 days after completion of radiotherapy. Multivariable analysis identified Body Mass Index (BMI), tumor volume (TV), and Prognostic Nutritional Index (PNI) as independent predictors for ARP. Their odds ratios (OR) and 95% confidence intervals (95% CI) were as follows: BMI (0.394, 0.230–0.675, P < 0.001), TV (2.242, 1.366–3.680, P = 0.001), and PNI (0.470, 0.279–0.790, P = 0.004). The nomogram showed moderate discriminative ability, with an AUC of 0.689 (95% CI [0.629–0.749]) in the training cohort and 0.725 (95% CI [0.636–0.815]) in the validation cohort. Calibration curves showed acceptable agreement between predicted and observed risks, and DCA suggested potential clinical usefulness within a range of threshold probabilities.
Conclusion
Lower BMI and PNI, and higher TV were independent predictors for ARP in LARC patients receiving nCRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, China.
- Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors, Fujian Medical University, Fuzhou, China.
- Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological and Breast Malignancies), Fuzhou, China.
Zitieren
APA
Wang, Y., Hong, Y., Wang, Y., Lin, J., Guan, H., Zhou, Z., & Xu, B. (2026). Nomogram based on Prognostic Nutritional Index (PNI) for predicting acute radiation proctitis in locally advanced rectal cancer patients with neoadjuvant chemoradiotherapy. PeerJ, 14, e21364. https://doi.org/10.7717/peerj.21364
Vancouver
Wang Y, Hong Y, Wang Y, Lin J, Guan H, Zhou Z, et al. Nomogram based on Prognostic Nutritional Index (PNI) for predicting acute radiation proctitis in locally advanced rectal cancer patients with neoadjuvant chemoradiotherapy. PeerJ. 2026;14:e21364. doi:10.7717/peerj.21364
BibTeX
@article{Wang2026,
author = {Wang, Yao and Hong, Yafang and Wang, Ying and Lin, Junjian and Guan, Hongdan and Zhou, Zihan and Xu, Benhua},
title = {Nomogram based on Prognostic Nutritional Index (PNI) for predicting acute radiation proctitis in locally advanced rectal cancer patients with neoadjuvant chemoradiotherapy},
journal = {PeerJ},
year = {2026},
volume = {14},
pages = {e21364},
doi = {10.7717/peerj.21364}
}
EUVIMED